Chat
Feedback
Settings

Settings

Goto Application

741,476 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07D

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 74,148
1.EP3514151PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE
FI - 04.07.2025
Int.Class C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
 Appl.No EP19160124.4 Applicant Novartis AG Inventor LUZZIO, Michael Joseph
2.WO/2025/140279QUATERNARY AMMONIUM COMPOUND AND PHARMACEUTICAL USE THEREOF
WO - 03.07.2025
Int.Class C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
 Appl.No PCT/CN2024/142210 Applicant SHANGHAI SENHUI MEDICINE CO., LTD. Inventor ZHU, Lingjian
The present disclosure relates to a quaternary ammonium compound and a pharmaceutical use thereof. Specifically, the present disclosure relates to a compound represented by formula IA or a pharmaceutically acceptable salt thereof, each substituent being as defined in the description.
3.WO/2025/140594ASYMMETRIC CATIONIC LIPID CONTAINING MULTIPLE TERTIARY AMINES
WO - 03.07.2025
Int.Class C07D 295/13
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
295Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
04with substituted hydrocarbon radicals attached to ring nitrogen atoms
12substituted by singly or doubly bound nitrogen atoms
125with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
13to an acyclic saturated chain
 Appl.No PCT/CN2024/143282 Applicant XIAMEN SINOPEG BIOTECH CO., LTD Inventor LIN, Minggui
The present invention belongs to the field of drug delivery. Provided is an asymmetric cationic lipid containing multiple tertiary amines, of which the structure is shown as a general formula (1), wherein the definition of each symbol is consistent with that in the description. In the present invention, a degradable group is introduced into a proper position of the cationic lipid, and the presence of the degradable group enables an LNP-drug composition prepared from the cationic lipid to be degradable in endosomes at a proper time and to have small cytotoxicity, thereby solving the problem that in the prior art, LNP-drug compositions prepared from non-degradable lipids will accumulate in endosomes and acidify the endosomal environment, which hinders the endosomal escape of drugs (such as mRNAs) and causes that the drugs delivered into cells fail to sufficiently exert the therapeutic effects. The cationic lipid in the present invention uses a heterofunctionalized piperazine-containing small molecule as a raw material, involves a simple preparation process and a lower cost, and is more green and environmentally-friendly. An LNP-mRNA composition prepared from the cationic lipid has the advantages of low toxicity, high biocompatibility, high cell transfection, etc.
4.WO/2025/140369COMPOUNDS WITH TWO AZAHETEROCYCLES SUBSTITUTED ISOINDOLINONE SKELETON AND USES THEREOF
WO - 03.07.2025
Int.Class C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
 Appl.No PCT/CN2024/142598 Applicant GLUETACS THERAPEUTICS (SHANGHAI) CO., LTD. Inventor YANG, Xiaobao
The present disclosure relates to a compound represented by formula (I) or a salt, enantiomer, stereoisomer, solvate, polymorph thereof and a use thereof. The present disclosure also relates to pharmaceutical compositions comprising, as an active ingredient, the compound represented by formula (I) or the salt, enantiomer, stereoisomer, solvate, polymorph thereof, and a use thereof. In the present disclosure, the compounds designed and synthesized can effectively prevent or treat diseases or conditions related to celeblon protein, including tumors or cancers.
5.WO/2025/144899USE OF MELANOCORTIN-4 RECEPTOR AGONISTS FOR THE TREATMENT OF A LEPR AND/OR SH2B1 DEFICIENCY
WO - 03.07.2025
Int.Class A61K 31/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
 Appl.No PCT/US2024/061918 Applicant LG CHEM, LTD. Inventor PARK, Hee, Dong
The present disclosure relates to the use of a compound of chemical Formula 1 or a pharmaceutically acceptable salt thereof for the purpose of preventing, improving, or treating a genetic obesity disease associated with the melanocortin-4 receptor (MC4R) pathway, particularly a genetic obesity disease associated with SH2B1 deficiency or a LEPR deficiency.
6.WO/2025/141029SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO - 03.07.2025
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
 Appl.No PCT/EP2024/088325 Applicant SANOFI Inventor DEPRETS, Stephanie Daniele
Disclosed are compounds of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed are a medicament and a pharmaceutical composition comprising said compounds of formula (I), and said compounds (I) for use in the treatment of a neurodegenerative disease such as Parkinson's disease. Further disclosed are a solid form of a compound of Formula (I-a), characterized as crystalline Form A, as well as a pharmaceutical composition comprising said solid form, and said solid form for use in treating a neurodegenerative disease.
7.WO/2025/142589COMPOUND OR SALT OR SOLVATE THEREOF, USE THEREOF, AND METHOD FOR PRODUCING SAME
WO - 03.07.2025
Int.Class C07D 417/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
 Appl.No PCT/JP2024/044401 Applicant NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY Inventor HANYU, Masayuki
The present disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts or solvates thereof: in formula (I), X1 and X2 each independently are a radioactive halogen nuclide, hydrogen, or deuterium, R1, R2, and R3 each independently are hydrogen or deuterium, at least one of X1, X2, R1, R2, and R3 is deuterium, at least one of X1 and X2 is a radioactive halogen nuclide, and Y is a methyl group and an isopropyl group.
8.WO/2025/144929BIODEGRADABLE LIPIDS AND FORMULATIONS FOR DELIVERY OF MRNA
WO - 03.07.2025
Int.Class C07D 259/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
259Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms
 Appl.No PCT/US2024/061952 Applicant MASSACHUSETTS INSTITUTE OF TECHNOLOGY Inventor ANDERSON, Daniel, Griffith
Provided herein are compounds, such as compounds of Formulae (I), (I'), (XI), (XII), and (XIII), and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and isotopically labeled derivatives thereof, and compositions, methods, uses, and kits thereof. The compounds provided herein are lipids useful for delivery of agents, including polynucleotides such as mRNA, for the treatment and/or prevention of various diseases and conditions (e.g., genetic diseases, proliferative diseases, hematological diseases, neurological diseases, liver diseases, spleen diseases, lung diseases, painful conditions, psychiatric disorders, musculoskeletal diseases, metabolic disorders, inflammatory diseases, and autoimmune diseases). Also provided herein are methods of synthesis of compounds of Formulae (I'), (XI), (XII), (XIII), and (VIII).
9.WO/2025/140595ASYMMETRIC CATIONIC LIPID HAVING BRANCHED PIPERAZINE RING
WO - 03.07.2025
Int.Class C07D 295/088
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
295Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
04with substituted hydrocarbon radicals attached to ring nitrogen atoms
08substituted by singly bound oxygen or sulfur atoms
084with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
088to an acyclic saturated chain
 Appl.No PCT/CN2024/143287 Applicant XIAMEN SINOPEG BIOTECH CO., LTD Inventor WEI, Guohua
The present invention belongs to the field of drug delivery. Provided is an asymmetric cationic lipid containing a branched piperazine ring and having a structure as shown in general formula (1), wherein the definition of each symbol is consistent with that described in the text. In the cationic lipid of the present invention, a degradable group is introduced at an appropriate position, and the presence of the degradable group makes an LNP-pharmaceutical composition prepared therefrom be degraded at an appropriate time in vivo and have a low cytotoxicity, which solves the problems in the prior art that an LNP-pharmaceutical composition prepared from a non-degradable lipid can accumulate in endosomes and acidify the endosomal environment, so that the endosomal escape of a drug (e.g., mRNA) is hindered, and the drug delivered into cells cannot fully function. In the cationic lipid of the present invention, a heterofunctionalized small molecule containing a piperazine ring is used as a raw material. The preparation process is simple and convenient, has a lower cost, and is more environmentally friendly. The LNP-mRNA composition prepared therefrom has the advantages of low toxicity, high biocompatibility, high cell transfection, etc.
10.WO/2025/140655HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS
WO - 03.07.2025
Int.Class C07D 213/89
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
213Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02having three double bonds between ring members or between ring members and non-ring members
89with hetero atoms directly attached to the ring nitrogen atom
 Appl.No PCT/CN2024/143464 Applicant FUJIAN HAIXI PHARMACEUTICALS CO., LTD. Inventor WANG, Ruyong
The present disclosure provides compounds of formula (I) having receptor protein tyrosine kinase activity, and a pharmaceutically acceptable salt, stereoisomers, isotopic isomers thereof. The compounds of the present disclosure have high biological activity and can be used to treat diseases or disorders related to the target.
# -